Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Portage Biotech - Stock

Portage Biotech Stock

PRTG
VGG7185A1286
A2P6BP

Price

0.18
Today +/-
+0
Today %
+0 %
P

Portage Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Portage Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Portage Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Portage Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Portage Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Portage Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Portage Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Portage Biotech’s growth potential.

Portage Biotech Revenue, EBIT and net profit per share

DatePortage Biotech RevenuePortage Biotech EBITPortage Biotech Net Income
2029e63.14 M undefined0 undefined47.21 M undefined
2028e2.55 M undefined-61.2 M undefined-21.79 M undefined
2027e0 undefined-49.98 M undefined-29.86 M undefined
2026e0 undefined-18.79 M undefined-10.49 M undefined
2025e0 undefined-16.75 M undefined-10.49 M undefined
2024e0 undefined-19.74 M undefined-13.11 M undefined
20230 undefined-16.57 M undefined-104.61 M undefined
20220 undefined-15.59 M undefined-16.87 M undefined
20210 undefined-12.44 M undefined-15.83 M undefined
20200 undefined-5.98 M undefined-5.33 M undefined
20190 undefined-2.76 M undefined-2.64 M undefined
20180 undefined-2.24 M undefined123.74 M undefined
20170 undefined-35.49 M undefined16.3 M undefined
20160 undefined-9.19 M undefined-5.71 M undefined
20150 undefined-4.32 M undefined-3.12 M undefined
20140 undefined-2.79 M undefined-6.3 M undefined
2013100,000 undefined-1.26 M undefined-1.47 M undefined
20120 undefined-1.62 M undefined-2.49 M undefined
20110 undefined-2.38 M undefined-3.67 M undefined
2010-780,000 undefined-3.18 M undefined-3.6 M undefined
200950,000 undefined-660,000 undefined-610,000 undefined
2008310,000 undefined-420,000 undefined-560,000 undefined
2007740,000 undefined-40,000 undefined-160,000 undefined

Portage Biotech Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000000000000000263
----------------------3,050.00
-----------------------
00000000000000000000000
000-3-2-1-1-2-4-9-35-2-2-5-12-15-16-19-16-18-49-610
----------------------3,050.00-
000-3-3-2-1-6-3-516123-2-5-15-16-104-13-10-10-29-2147
------33.33-50.00500.00-50.0066.67-420.00668.75-101.63150.00200.006.67550.00-87.50-23.08-190.00-27.59-323.81
0.270.290.30.430.780.790.81.621.932.42.722.74.8210.9511.7313.0616.12000000
- - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Portage Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Portage Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Portage Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Portage Biotech's financial health and stability.

Assets

Portage Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Portage Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Portage Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Portage Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
000-3-3-2-1-6-4-90123-3-7-17-19-104
00000000000000000
0000000000000024-17
00020000000000000
00011004130-12423118110
00000000000000000
00000000000000000
0000-2-1-1-1-2-5-1-10-3-4-6-12
000-40000000000000
0-10-301500-1-3500000
0-10001500-1-3500000
00000000000000000
0001,000-1,00000000000000-2,000
100520002602006292
1006000321002004270
0000-1003040001-1-1-1
00000000000000000
0-101-103102-47-1-3020-12
-0.53-0.48-0.32-4.63-2.82-1.35-1.82-1.94-2.61-5.84-1.32-1.07-0.86-3.71-4.28-6.76-12.07
00000000000000000

Portage Biotech stock margins

The Portage Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Portage Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Portage Biotech.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Portage Biotech's sales revenue. A higher gross margin percentage indicates that the Portage Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Portage Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Portage Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Portage Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Portage Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Portage Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Portage Biotech Margin History

Portage Biotech Gross marginPortage Biotech Profit marginPortage Biotech EBIT marginPortage Biotech Profit margin
2029e0 %0 %74.77 %
2028e0 %-2,400 %-854.5 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %-1,260 %-1,470 %
20120 %0 %0 %
20110 %0 %0 %
20100 %407.69 %461.54 %
20090 %-1,320 %-1,220 %
20080 %-135.48 %-180.65 %
20070 %-5.41 %-21.62 %

Portage Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Portage Biotech earnings per share therefore indicates how much revenue Portage Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Portage Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Portage Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Portage Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Portage Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Portage Biotech Revenue, EBIT and net profit per share

DatePortage Biotech Sales per SharePortage Biotech EBIT per sharePortage Biotech Earnings per Share
2029e3.19 undefined0 undefined2.39 undefined
2028e0.13 undefined0 undefined-1.1 undefined
2027e0 undefined0 undefined-1.51 undefined
2026e0 undefined0 undefined-0.53 undefined
2025e0 undefined0 undefined-0.53 undefined
2024e0 undefined0 undefined-0.66 undefined
20230 undefined-1.03 undefined-6.49 undefined
20220 undefined-1.19 undefined-1.29 undefined
20210 undefined-1.06 undefined-1.35 undefined
20200 undefined-0.55 undefined-0.49 undefined
20190 undefined-0.57 undefined-0.55 undefined
20180 undefined-0.83 undefined45.83 undefined
20170 undefined-13.05 undefined5.99 undefined
20160 undefined-3.83 undefined-2.38 undefined
20150 undefined-2.24 undefined-1.62 undefined
20140 undefined-1.72 undefined-3.89 undefined
20130.13 undefined-1.57 undefined-1.84 undefined
20120 undefined-2.05 undefined-3.15 undefined
20110 undefined-3.05 undefined-4.71 undefined
2010-1.81 undefined-7.4 undefined-8.37 undefined
20090.17 undefined-2.2 undefined-2.03 undefined
20081.07 undefined-1.45 undefined-1.93 undefined
20072.74 undefined-0.15 undefined-0.59 undefined

Portage Biotech business model

Portage Biotech Inc is an international biotechnology company based in Canada. The company was established in 2015 as a holding company and took control of the stock of Biohaven Pharmaceutical Holding Company. Portage Biotech operates in various locations, including Canada, the US, and Europe. The business model of Portage Biotech is based on identifying promising new technologies and creating companies that utilize these technologies. The company employs a strategic investment strategy, acquiring stakes in promising biotechnology companies and working closely with them to bring their products and therapies to market. Another strategy of Portage Biotech is the establishment of innovation centers in different countries. This involves bringing together highly skilled personnel and cutting-edge technologies under one roof to create innovative products and solutions that can be brought to the global market. The company also operates in several business areas, including medical research and development. In this field, Portage Biotech works on developing new therapies, particularly in the field of cancer research. Additionally, the company has a division for medical diagnostics, where innovative testing procedures are developed to contribute to early disease detection. Another important business area for Portage Biotech is the manufacturing of biopharmaceuticals, which are drugs based on biological agents. The company collaborates closely with other biotechnology companies to bring innovative products to the market. Portage Biotech has already successfully implemented a number of promising projects, including the development of therapies for cancer, Alzheimer's, and Parkinson's. The company also has promising biosimilars and biosuperior products in the pipeline that could revolutionize the market. To successfully execute these projects, Portage Biotech has assembled an impressive leadership team. The company has an experienced team of scientists, managers, and professionals who are dedicated to finding the best solutions for the challenges of the biotechnology industry. Overall, Portage Biotech is an innovative company that focuses on the discovery and promotion of promising new technologies. The company has already achieved an impressive track record and has the potential to play a revolutionary role in the field of biotechnology. Portage Biotech is one of the most popular companies on Eulerpool.com.

Portage Biotech SWOT Analysis

Strengths

Portage Biotech Inc has several strengths that contribute to its competitive advantage in the industry. Firstly, the company possesses a strong and experienced management team with a proven track record in the healthcare sector. This provides them with valuable expertise and insights to drive strategic decision-making.

Secondly, Portage Biotech Inc has a robust pipeline of innovative biotechnology products and therapies. These promising advancements in healthcare offer potential for significant revenue generation and future growth. Additionally, the company has established successful collaborations with leading research institutions and pharmaceutical partners, enhancing their access to resources and expertise.

Weaknesses

Despite its strengths, Portage Biotech Inc also faces some weaknesses that could impact its performance. One of the main weaknesses is the heavy reliance on external funding sources for research and development. This exposes the company to potential financial constraints and uncertainties in securing necessary investments for continued growth.

Another weakness lies in the competitive nature of the biotechnology industry. Portage Biotech Inc operates in a highly dynamic and rapidly evolving market, which presents challenges in terms of keeping up with technological advancements and staying ahead of competitors. Additionally, the company's relatively small size and limited resources may hinder its ability to compete with larger and more established players in the industry.

Opportunities

Portage Biotech Inc has several opportunities to capitalize on in the biotechnology sector. Firstly, the increasing demand for personalized medicine and targeted therapies presents a favorable market landscape for the company's innovative products. By leveraging their expertise and pipeline, the company can tap into this growing market segment and gain a competitive edge.

Additionally, strategic partnerships and collaborations with research institutions and pharmaceutical companies offer opportunities for knowledge-sharing, resource pooling, and potential synergies. These collaborations can accelerate the development and commercialization of Portage Biotech Inc's products and expand their market presence.

Threats

Portage Biotech Inc faces certain threats that could impact its operations and performance. One significant threat is the stringent regulatory environment governing the biopharmaceutical industry. Compliance with complex regulations and requirements can result in delays in product development and approvals, increasing time to market and potentially affecting revenue generation.

Another threat comes from the potential for intellectual property infringement and patent disputes. Protecting and enforcing intellectual property rights is crucial for Portage Biotech Inc to safeguard their investments and maintain a competitive advantage. Failure to do so may expose the company to legal disputes, loss of exclusivity, and potential revenue loss.

Portage Biotech valuation based on historical P/E ratio, EBIT, and P/S ratio.

Portage Biotech shares outstanding

The number of shares was Portage Biotech in 2023 — This indicates how many shares 16.12 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Portage Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Portage Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Portage Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Portage Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Portage Biotech Stock splits

In Portage Biotech's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Portage Biotech.

Portage Biotech Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2023-0.28 0.01  (103.63 %)2024 Q3
6/30/2023-0.24 -0.33  (-34.8 %)2024 Q1
3/31/2023-5.54 -5.86  (-5.8 %)2023 Q4
12/31/2022-0.24 -0.44  (-84.87 %)2023 Q3
9/30/2022-0.3 -0.06  (79.72 %)2023 Q2
6/30/2022-0.3 -0.13  (57.04 %)2023 Q1
3/31/2022-0.28 -0.56  (-98.44 %)2022 Q4
12/31/2021-0.28 -0.26  (6.74 %)2022 Q3
9/30/2021-0.26 -0.22  (14.86 %)2022 Q2
6/30/2021-0.21 -0.25  (-16.71 %)2022 Q1
1

Portage Biotech Stock Shareholders

%
Name
Stocks
Change
Date
9.48 % Armistice Capital LLC1,876,105-92,00012/31/2023
3.61 % SalvaRx Group Plc713,19103/31/2023
17.66 % Bailey (Gregory Hugh)3,494,09591,9007/30/2023
15.36 % Mellon (James)3,039,0047,2837/30/2023
1.09 % Walters (Ian B.)215,091-87,5193/31/2023
1.08 % Bison Wealth, LLC213,398012/31/2023
0.71 % Kramer (Robert)140,73403/31/2023
0.28 % Mintz (Steven Michael)55,3112,0733/31/2023
0.26 % Peak 6 Capital Management, LLC51,22151,22112/31/2023
0.15 % BlackRock Institutional Trust Company, N.A.29,068-28212/31/2023
1
2
3
4
5
...
7

Portage Biotech Executives and Management Board

Dr. Ian Walters
Portage Biotech Chairman of the Board, Chief Executive Officer (since 2016)
Compensation 1.72 M
Mr. Allan Shaw58
Portage Biotech Chief Financial Officer, Secretary
Compensation 873,389
Mr. Justin Fairchild
Portage Biotech Vice President - Development
Compensation 790,463
Mr. Steven Innaimo
Portage Biotech Vice President - Project Management and Operations
Compensation 520,689
Mr. Robert Kramer
Portage Biotech Chief Scientific Officer
Compensation 447,611
1
2
3

Portage Biotech stock: Frequently Asked Questions

What values and corporate philosophy does Portage Biotech represent?

Portage Biotech Inc represents a strong commitment to innovation, scientific excellence, and patient-centricity. As a leading biotechnology company, Portage Biotech is dedicated to discovering and developing breakthrough therapies to address unmet medical needs. Their corporate philosophy centers around collaboration, transparency, and ethical practices, ensuring the highest standards of integrity in all aspects of their research and business operations. Portage Biotech embraces a patient-first approach, striving to improve the lives of individuals and contribute to advancements in healthcare through their cutting-edge drug development programs.

In which countries and regions is Portage Biotech primarily present?

Portage Biotech Inc is primarily present in the United States, Canada, and Europe. With offices and operations in these countries and regions, Portage Biotech Inc extends its reach and presence in the global biotech market. This multinational presence allows the company to tap into various markets, collaborate with international partners, and access a diverse pool of resources and expertise. With a firm foothold in these key locations, Portage Biotech Inc is well-positioned to drive innovation, facilitate research and development, and deliver cutting-edge biotech solutions worldwide.

What significant milestones has the company Portage Biotech achieved?

Portage Biotech Inc has achieved several significant milestones. These include successfully advancing their pipeline of novel immunotherapy and targeted therapy candidates, securing partnerships with leading pharmaceutical companies for the development and commercialization of their products, and obtaining regulatory approvals for clinical trials. The company has also demonstrated promising results in early-stage studies, showcasing their potential for addressing unmet medical needs. With a strong focus on innovation and collaboration, Portage Biotech Inc continues to strive towards enhancing patient outcomes and making a meaningful impact in the field of biotechnology.

What is the history and background of the company Portage Biotech?

Portage Biotech Inc, a leading clinical-stage biopharmaceutical company, has a rich history and compelling background. Established in [year], Portage Biotech has been dedicated to discovering and developing innovative therapies that address unmet medical needs. With a focus on oncology and immunology, the company aims to deliver groundbreaking advancements in cancer treatment and autoimmune diseases. Portage Biotech's team of industry experts and seasoned scientists bring a wide range of experience to the table, leveraging cutting-edge research and strategic partnerships to advance their mission. As a result, Portage Biotech Inc has become a respected name in the biotechnology sector, consistently working towards improving patients' lives through their revolutionary therapies.

Who are the main competitors of Portage Biotech in the market?

The main competitors of Portage Biotech Inc in the market include prominent biopharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, Roche, and AstraZeneca. These companies are also engaged in developing innovative biotech solutions and therapies, posing competition to Portage Biotech Inc.

In which industries is Portage Biotech primarily active?

Portage Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Portage Biotech?

The business model of Portage Biotech Inc is focused on the development and commercialization of innovative therapeutics to address significant unmet medical needs. The company primarily focuses on advancing its portfolio of immuno-oncology assets, aiming to bring novel treatments to patients with various types of cancer. Portage Biotech Inc strives to identify and acquire promising drug candidates or early-stage technologies with strong therapeutic potential. Through strategic collaborations and partnerships, the company aims to accelerate the development and ultimately obtain regulatory approvals for its pipeline products. By capitalizing on novel scientific advancements, Portage Biotech Inc aims to revolutionize the treatment landscape and improve patient outcomes in the field of oncology.

What is the P/E ratio of Portage Biotech 2024?

The Portage Biotech P/E ratio is -0.22.

What is the P/S ratio of Portage Biotech 2024?

The Portage Biotech P/S ratio is 0.

What is the AlleAktien quality score of Portage Biotech?

The AlleAktien quality score for Portage Biotech is 4/10.

What is the revenue of Portage Biotech 2024?

The revenue cannot currently be calculated for Portage Biotech.

How high is the profit of Portage Biotech 2024?

The expected Portage Biotech profit is -13.11 M USD.

What is the business model of Portage Biotech

Portage Biotech Inc is an innovative biotechnology company focused on developing therapeutic products to combat diseases such as cancer, Alzheimer's, and Parkinson's. The company's business model is based on a specialized pipeline of product candidates developed by a highly qualified team of leading scientists, biotechnology engineers, and clinical experts. Portage Biotech operates in multiple divisions, including Portage Pharmaceuticals, Portage BioAnalytics, and Biohaven Pharmaceuticals. The company's portfolio includes groundbreaking products such as PPL-003, BNC210, and Trastuzumab Biosimilar. Portage Biotech utilizes innovative technologies and collaborations to develop solutions and advance groundbreaking medications. The company aims to continually innovate its products and meet the needs of patients and customers worldwide, making it a significant player in the biotechnology sector.

What is the Portage Biotech dividend?

Portage Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Portage Biotech pay dividends?

The dividend cannot currently be calculated for Portage Biotech or the company does not pay out a dividend.

What is the Portage Biotech ISIN?

The ISIN of Portage Biotech is VGG7185A1286.

What is the Portage Biotech WKN?

The WKN of Portage Biotech is A2P6BP.

What is the Portage Biotech ticker?

The ticker of Portage Biotech is PRTG.

How much dividend does Portage Biotech pay?

Over the past 12 months, Portage Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Portage Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Portage Biotech?

The current dividend yield of Portage Biotech is .

When does Portage Biotech pay dividends?

Portage Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Portage Biotech?

Portage Biotech paid dividends every year for the past 0 years.

What is the dividend of Portage Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Portage Biotech located?

Portage Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Portage Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Portage Biotech from 7/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did Portage Biotech pay the last dividend?

The last dividend was paid out on 7/5/2024.

What was the dividend of Portage Biotech in the year 2023?

In the year 2023, Portage Biotech distributed 0 USD as dividends.

In which currency does Portage Biotech pay out the dividend?

The dividends of Portage Biotech are distributed in USD.

Other fundamentals and analyses of Portage Biotech in the deep dive.

Our stock analysis for Portage Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Portage Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.